Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

Clopidogrel loading offers little added benefit for stenosis patients pre-TAVI

P2Y12 inhibitor initiation with clopidogrel using a loading dose (LD) is no more effective in reducing ischemic events or adverse outcomes in transcatheter aortic valve implantation (TAVI) patients than initiating the therapy without a loading dose, according to research published in the American Journal of Cardiology Feb. 10.

FDA fast-tracks review process for cardiac amyloidosis drug

Tafamidis, Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has been granted a priority review designation from the FDA, potentially speeding its path to approval.

Thumbnail

CDK2 inhibitors protect cancer patients from anthracycline-induced cardiotoxicity

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Thumbnail

Why Cleveland Clinic began screening carpal tunnel patients for cardiac amyloidosis

Cleveland Clinic researchers identified amyloid deposits in 10.2 percent of patients undergoing carpal tunnel release surgery, suggesting biopsies of hand tissue could be an early signal of life-threatening cardiac amyloidosis.

Thumbnail

Tafamidis shows promise for treating cardiac amyloidosis

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Higher statin doses tied to fewer deaths, amputations in PAD patients

High-intensity statin therapy for peripheral artery disease (PAD) patients reduces the risk of lower-extremity amputations by one-third and the risk of mortality by 26 percent, a new study found. However, the lipid-lowering drugs remain underutilized in the PAD population despite their guideline-recommended use.

Thumbnail

ACC, SCAI, HRS release consensus statement on left atrial appendage occlusion requirements

Three leading cardiology societies released a consensus statement on Dec. 10 regarding criteria institutions and operators should follow for left atrial appendage occlusion.

Displaying 281 - 288 of 293

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.